

[Artesunate](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BE03](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Artesunate

Medicine type

Chemical agent

List type

Core

Additional notes

For use in the management of severe malaria

Formulations

Parenteral > General injections > IV: 60 mg in vial powder for injection ; 30 mg in vial powder for injection ; 120 mg in vial powder for injection

Local > Rectal > Other: 100 mg capsules (EMLc)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2017 ([TRS 1006](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artesunate](#)

DrugBank

[Artesunate](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of artesunate powder for injection 30 mg, 60 mg and 120 mg on the EML and EMLc; - the deletion of the previously listed injection formulation of artesunate from the EML and EMLc; - the deletion of 50 mg and 200 mg artesunate rectal capsules from the EML and EMLc; - the deletion of 50 mg artesunate tablets from the EML and EMLc. - the removal of footnotes regarding follow-up care and combination use.